Hayrettin TEMEL, Cihangir AKGÜN, Mesut OKUR

The Relationship Between IgA Vasculitis and Antioxidant Activity In Children

Objective: Immunoglobulin A vasculitis (IgAV) is the most common systemic vasculitis seen in children. The aim of this study is to investigate the relationship between malondialdehyde-induced oxidative stress, antioxidant system and organ involvement in IgAV patients. Method: 32 patients and 28 healthy children were included in the study. Serum malondialdehyde, reduced glutathione, vitamin E, vitamin C, retinol, and beta-carotene levels were measured in patients (separately in both the active and remission phases) and healthy children. Results: MDA levels were significantly higher in patients with active phase while reduced glutathione and vitamin C levels were markedly lower in both the active and the remission phases. Retinol and beta-carotene levels were lower in the active phase. It was found that retinol levels were significantly lower in patients with gastrointestinal system involvement compared to those without. Vitamin C levels were significantly lower in those with kidney involvement compared to those without. Also, a negative correlation was observed between retinol levels and the number of organs involved. Conclusion: We consider that especially vitamin C and vitamin A may be used in the treatment of IgAV. However, whether the derangements of the oxidant/antioxidant balance in the direction of increased oxidative stress are consequences or causes of the events occurring in the active phase of IgAV are open to further investigation.

Çocuklarda IgA Vasküliti ile Antioksidan Aktivite Arasındaki İlişki

Amaç: İmmünoglobulin A vaskülit (IgAV) çocuklarda en sık görülen sistemik vaskülittir. Bu çalışmanın amacı, IgAV hastalarında malondialdehit kaynaklı oksidatif stres, antioksidan sistem ve organ tutulumu arasındaki ilişkiyi araştırmaktır. Yöntemler: Çalışmaya 32 hasta ve 28 sağlıklı çocuk dahil edildi. Hastalarda (hem aktif hem de remisyon fazlarında ayrı ayrı) ve sağlıklı çocuklarda serum malondialdehit, redükte glutatyon, E vitamini, C vitamini, retinol ve beta-karoten seviyeleri ölçüldü. Bulgular: Aktif fazı olan hastalarda MDA seviyeleri önemli ölçüde daha yüksekken, redükte glutatyon ve C vitamini seviyeleri hem aktif hem de remisyon fazlarında belirgin şekilde daha düşüktü. Retinol ve beta-karoten seviyeleri aktif fazda daha düşüktü. Gastrointestinal sistem tutulumu olan hastalarda retinol düzeylerinin olmayanlara göre anlamlı derecede düşük olduğu bulundu. Böbrek tutulumu olanlarda, olmayanlara göre C vitamini seviyeleri önemli ölçüde daha düşüktü. Ayrıca, retinol seviyeleri ile ilgili tutulan organ sayısı arasında negatif bir korelasyon gözlendi. Sonuç: IgAV tedavisinde özellikle C vitamini ve A vitamininin kullanılabileceğini düşünüyoruz. Bununla birlikte, oksidan / antioksidan dengesindeki artmış oksidatif stres yönündeki düzensizliklerin, IgAV'nin aktif fazında meydana gelen olayların sonuçları mı yoksa nedenleri mi olduğu daha fazla araştırmaya açıktır.

PDF

___

1.Jennette JC, Falk RJ, Bacon PA, et al. 2012 RevisedInternational Chapel Hill Consensus ConferenceNomenclature of Vasculitides. Arthritis Rheum.2013; 65: 1-11.

2.Piram M, Mahr A. Epidemiology ofimmunoglobulin A vasculitis (Henoch-Schönlein):current state of knowledge. Curr Opin Rheumatol.2013 ;25: 171-8.

3.Rigante D, Castellazzi L, Bosco A, et al. Is there acrossroad between infections, genetics, and Henoch-Schönlein purpura?. Autoimmun Rev. 2013; 12:1016-21.

4.Kattoor AJ, Pothineni NVK, Palagiri D, et al.Oxidative Stress in Atherosclerosis. CurrAtheroscler Rep. 2017; 19: 42.

5.Dalbaşı E, Gedı̇k E, Tüzün A, Obay B. Correlation ofMalondialdehyde and Antioxidant Enzyme Levelswith Peritonitis Severity in Patients withGeneralized Peritonitis. Dicle Med Journal. 2020; 47:293-03.

6.Lü JM, Lin PH, Yao Q, Chen C. Chemical andmolecular mechanisms of antioxidants:experimental approaches and model systems. J CellMol Med. 2010; 14: 840-60.

7.Narayanankutty A, Job JT, Narayanankutty V.Glutathione, an Antioxidant Tripeptide: Dual Rolesin Carcinogenesis and Chemoprevention. CurrProtein Pept Sci. 2019; 20: 907-17.

8.Engin KN. Alpha-tocopherol: looking beyond anantioxidant. Mol Vis. 2009; 15: 855-60.

9.Berger MM, Oudemans-van Straaten HM. VitaminC supplementation in the critically ill patient. CurrOpin Clin Nutr Metab Care. 2015; 18: 193-201.

10.Sies H, Stahl W. Vitamins E and C, beta-carotene,and other carotenoids as antioxidants. Am J ClinNutr. 1995; 62: 1315-21.

11.P. Padmanabhan, A. Cheema, G. Paliyath,Solanaceous Fruits Including Tomato, Eggplant, andPeppers. Encyclopedia of Food and Health, 1st edn.Oxford: Academic Press, 2016; 24-32.

12.Vance TM, Su J, Fontham ET, et al. Dietaryantioxidants and prostate cancer: a review. NutrCancer. 2013; 65: 793-801.

13.Túri S, Németh I, Torkos A, et al. Oxidative stressand antioxidant defense mechanism in glomerulardiseases. Free Radic Biol Med. 1997; 22: 161-68.

14.Demircin G, Oner A, Unver Y, et al. Erythrocytesuperoxide dismutase activity and plasmamalondialdehyde levels in children with HenochSchönlein purpura. Acta Paediatr. 1998; 87: 848-52.

15.Mills JA, Michel BA, Bloch DA, et al. The AmericanCollege of Rheumatology 1990 criteria for theclassification of Henoch-Schönlein purpura.Arthritis Rheum. 1990; 33: 1114-121.

16.Cassidy JT, Petty RE: Textbook of PediatricRheumatology: Leucocytoclastic vasculitis, 5th edn.Philadelphia, Elsevier Saunders, 2005; 496–512.

17.Ece A, Yolbaş İ, Balık H, et al. Henoch-Schönleinpurpura in childhood: Review of 214 patients, J ClinExp Invest. 2012; 3: 91-5.

18.Akça Ü, Akça G, Nalcacıoğlu H, et al. Evaluation ofepidemiological, clinical and laboratory findings inHenoch Schönlein purpura. Turkish Journal ofFamily Practice. 2020; 24: 87-94.

19.Peru H, Soylemezoglu O, Bakkaloglu SA, et al.Henoch Schonlein purpura in childhood: clinicalanalysis of 254 cases over a 3-year period. ClinRheumatol. 2008; 27:1087-92.

20.Trapani S, Micheli A, Grisolia F, et al. HenochSchonlein purpura in childhood: epidemiologicaland clinical analysis of 150 cases over a 5-yearperiod and review of literature. Semin ArthritisRheum. 2005; 35: 143-53.

21.Farley TA, Gillespie S, Rasoulpour M, et al.Epidemiology of a cluster of Henoch-Schönleinpurpura. Am J Dis Child. 1989; 143: 798-803.

22.Koçak M, Büyükkaragöz B, Can Y, et al. TheEpidemiological, Clinical and Laboratory Features of91 Children with Henoch-Schönlein Purpura. AbantMedical Journal. 2015; 4: 134-40.

23.Cakiter AU, Kucuk OS, Ozkaya DB, Topukcu B,Onsun N. Demographic characteristics, aetiology,and assessment of treatment options inleukocytoclastic vasculitis. Postepy DermatolAlergol. 2017; 34: 104-9.

24.Ekinci RMK, Balci S, Melek E, et al. Clinicalmanifestations and outcomes of 420 children withHenoch Schönlein Purpura from a single referralcenter from Turkey: A three-year experience. ModRheumatol. 2020; 30: 1039-46.

25.Buyan N, Erbaş D, Akkök N, et al. Role of freeoxygen radicals and prostanoids in the pathogenesisof Henoch-Schönlein Purpura. ProstaglandinsLeukot Essent Fatty Acids. 1998; 59: 181-4.

26.Erdoğan O, Oner A, Aydin A, et al. Effect ofvitamin E treatment on the oxidative damageoccurring in Henoch-Schönlein purpura. ActaPaediatr. 2003; 92: 546-50.

27.Ece A, Kelekçi S, Kocamaz H, et al. Antioxidantenzyme activities, lipid peroxidation, and totalantioxidant status in children with Henoch-Schönlein purpura. Clin Rheumatol. 2008; 27: 163-69.

28.Gurses D, Parlaz N, Bor Kucukatay M, et al.Evaluation of oxidative stress and erythrocyteproperties in children with henoch-shoenleinpurpura. Iran J Pediatr. 2014; 24: 166-72.